Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05183126 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
A Phase 4 study of Breast Cancer and Esophageal Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05183126 is a Phase 4 study of Breast Cancer and Esophageal Cancer that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 22 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05183126, a Phase 4 study of Breast Cancer and Esophageal Cancer, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Conditions Studied
Interventions
- DRUG Paclitaxel
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05183126
The ClinicalTrials.gov registry entry for NCT05183126 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel is the first listed.
NCT05183126 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05183126 about?
NCT05183126 is a clinical study titled "Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer". The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour ...
What is the current status of trial NCT05183126?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2022-03-28. Estimated completion is 2026-06.
What conditions does trial NCT05183126 study?
This clinical trial studies the following conditions: Breast Cancer, Esophageal Cancer, Metastatic Gastric Cancer.
What interventions are being tested in trial NCT05183126?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05183126?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05183126 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
RECRUITING · Phase 4
-
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.